89bio Announces Plans for Phase 2b (ENLIVEN) Trial in NASH,

ENLIVEN trial to initiate as planned in 2Q21 -. SAN FRANCISCO, April 05, 2021 (GLOBE NEWSWIRE) — 89bio, Inc. (Nasdaq: ETNB), a clinical-stage …, ENLIVEN trial to initiate as planned in 2Q21 -. SAN FRANCISCO, April 05, 2021 (GLOBE NEWSWIRE) — 89bio, Inc. (Nasdaq: ETNB), a clinical-stage …, Read More

Scroll to Top